Table 2:

CINV prophylaxis guidelines for patients receiving MEC regimens [2,10]

Guideline	Drug combination on day of chemotherapy	Drug combination on day 2+ after chemotherapy
MASCC	Palonosetron + dexamethasone	Dexamethasone
NCCN	5HT3 RA + dexamethasone ± NK-1 RA in selected patients ± lorazepam ± H2 blocker or proton pump inhibitor	5HT3 RA (unless NK-1 RA used on day 1) or dexamethasone or NK-1 RA in selected patients ± lorazepam ± H2 blocker or proton pump inhibitor

MASCC, Multinational Association of Supportive Care in Cancer; NCCN, National Comprehensive Cancer Network; 5HT₃ RA, 5-hydroxytryptamine type 3 receptor antagonists; NK-1 RA, neurokinin-1 receptor antagonists.